MARKET

AMGN

AMGN

Amgen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

213.64
-1.72
-0.80%
After Hours: 214.00 +0.36 +0.17% 19:57 09/22 EDT
OPEN
216.56
PREV CLOSE
215.36
HIGH
216.56
LOW
213.46
VOLUME
2.54M
TURNOVER
--
52 WEEK HIGH
276.69
52 WEEK LOW
210.28
MARKET CAP
121.32B
P/E (TTM)
21.72
1D
5D
1M
3M
1Y
5Y
Amgen To Present At The 2021 Cantor Global Healthcare Conference
/PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Cantor Global Healthcare Conference at 2:00 p.m. ET on . , senior vice president, Global Marketing, Access and Capabilities and , executive vice president and chief financial officer at Amgen will pre...
PR Newswire - PRF · 9h ago
Amgen Releases 8th Edition of Biosimilar Trends Report
Sept. 22, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today released the 8 edition of the Biosimilar Trends Report, which examines the current state of the U.S. biosimilars marketplace across inflammation, oncology and nephrology categories, while a new feat...
PR Newswire - PRF · 16h ago
Amgen blocks Sandoz, Zydus generics of psoriasis drug Otezla until 2028
Amgen has won a ruling in New Jersey federal court that blocks Sandoz Inc and Zydus Pharmaceuticals' proposed generics of its blockbuster psoriasis drug Otezla until 2028, the company said.
Reuters · 1d ago
Biosimilar Market Report 2021: Increased Investments, Product Launches, and Collaborations to Spur Growth – Forecast to 2026
The is expected to exceed more than US$ 23.50 Billion by 2024 at a CAGR of 31% in the given forecast period.
Heraldkeepers · 1d ago
Dow's 150-point jump highlighted by gains in American Express, Home Depot stocks
Marketwatch.com · 1d ago
Global Multiple Myeloma Treatment Drugs Market Global Industry Trends, Competition Strategies and Revenue Analysis 2029
Research Nester released a report titled which delivers detailed overview of the global multiple myeloma treatment drugs market in terms of market segmentation by drug class, therapy, distribution channel, and by region.
AmericaNewsHour · 1d ago
Global Sterile Injectable Drugs Market Growth to be Propelled by Increasing R&D Initiatives to Witness Considerable GAGR throughout 2021-2029
Research Nester released a report titled "" which delivers detailed overview of the global sterile injectable drugs market in terms of market segmentation by type, drug class, application, distribution channel, and by region.
AmericaNewsHour · 1d ago
Amgen Secures Favorable Ruling in Patent Dispute Against Sandoz, Zydus Over Psoriasis Drug
MT Newswires · 1d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AMGN. Analyze the recent business situations of Amgen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 27 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AMGN stock price target is 250.00 with a high estimate of 298.00 and a low estimate of 185.00.
EPS
Institutional Holdings
Institutions: 2.75K
Institutional Holdings: 463.60M
% Owned: 81.64%
Shares Outstanding: 567.85M
TypeInstitutionsShares
Increased
872
13.44M
New
107
4.36M
Decreased
842
21.29M
Sold Out
109
603.31K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.31%
Pharmaceuticals & Medical Research
-0.11%
Key Executives
Chairman/Chief Executive Officer/President/Director
Robert Bradway
Chief Financial Officer/Executive Vice President
Peter Griffith
Executive Vice President/General Counsel/Secretary
Jonathan Graham
Executive Vice President/Director of Human Resources
Lori Johnston
Executive Vice President
Murdo Gordon
Executive Vice President
David Reese
Executive Vice President
Esteban Santos
Senior Vice President
David Piacquad
Lead Director/Independent Director
Robert Eckert
Independent Director
Wanda Austin
Independent Director
Brian Druker
Independent Director
Gregory Garland
Independent Director
Charles Holley
Independent Director
S. Omar Ishrak
Independent Director
Tyler Jacks
Independent Director
Ellen Kullman
Independent Director
Amy Miles
Independent Director
Ronald Sugar
Independent Director
Robert Williams
Declaration Date
Dividend Per Share
Ex-Div Date
07/30/2021
Dividend USD 1.76
08/16/2021
03/03/2021
Dividend USD 1.76
05/14/2021
12/16/2020
Dividend USD 1.76
02/11/2021
10/21/2020
Dividend USD 1.6
11/13/2020
07/23/2020
Dividend USD 1.6
08/14/2020
03/04/2020
Dividend USD 1.6
05/15/2020
12/11/2019
Dividend USD 1.6
02/13/2020
10/22/2019
Dividend USD 1.45
11/14/2019
08/02/2019
Dividend USD 1.45
08/14/2019
03/07/2019
Dividend USD 1.45
05/16/2019
12/07/2018
Dividend USD 1.45
02/14/2019
10/23/2018
Dividend USD 1.32
11/15/2018
07/31/2018
Dividend USD 1.32
08/16/2018
03/07/2018
Dividend USD 1.32
05/16/2018
12/12/2017
Dividend USD 1.32
02/14/2018
10/24/2017
Dividend USD 1.15
11/16/2017
07/28/2017
Dividend USD 1.15
08/15/2017
03/07/2017
Dividend USD 1.15
05/15/2017
12/20/2016
Dividend USD 1.15
02/13/2017
10/14/2016
Dividend USD 1
11/14/2016
About AMGN
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Webull offers kinds of Amgen, Inc. stock information, including NASDAQ:AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.